In cetuximab-resistant human colorectal cancer cell lines LIM1215 and OXCO2, the treatment of AR-C155858 (Table 2), an inhibitor of MCT1 and MCT2, effectively restored their sensitivity to cetuximab. Here, SLC16A1 is linked to colorectal cancer.